@article{75c5951601b046f883e4465186a0aa7a,
title = "New Insights on Tramadol and Immunomodulation",
abstract = "Purpose of Review: Opioids are administered to cancer patients although concerns have been raised that they may promote tumour growth or metastasis owing to their ability to suppress anti-cancer immunity. Tramadol has been reported to preserve or promote the immune response and may therefore be preferred to other opioids in cancer patients. We reviewed the literature documenting the immunomodulatory effects of tramadol. Recent Findings: Recent clinical evidence appears to confirm that tramadol possesses anti-inflammatory properties, and preserves some signalling cascades of the immune system relevant to anti-cancer defence. Summary: Tramadol is reported to promote or preserve immunity including natural killer cell activity which is important in anti-cancer defences.",
keywords = "Cancer, Desmetramadol, Serotonin, Tramadol",
author = "Iqira Saeed and {la Caze}, Adam and Hollmann, {Markus W.} and Shaw, {Paul N.} and Marie-Odile Parat",
note = "Funding Information: Iqira Saeed declares that she has no conflict of interest. Adam La Caze declares that he has no conflict of interest. Markus W. Hollmann has received research funding from CSL Behring, ZonMw, the Society of Cardiovasular Anesthesiologists (SCA) and the European Association of Cardiothoracic Anaesthesiology (EACTA); and has received compensation from Eurocept Pharmaceuticals BV and IDD for service as a consultant. Paul N. Shaw declares that he has no conflict of interest. Marie-Odile Parat declares that she has no conflict of interest. Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",
year = "2021",
month = nov,
day = "1",
doi = "https://doi.org/10.1007/s11912-021-01121-y",
language = "English",
volume = "23",
journal = "Current oncology reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "11",
}